Alexion Pharmaceuticals Company Profile (NASDAQ:ALXN)

About Alexion Pharmaceuticals (NASDAQ:ALXN)

Alexion Pharmaceuticals logoAlexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous). Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS). PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system. Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP). Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). It is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:ALXN
  • CUSIP: 01535110
  • Web: www.alexion.com
Capitalization:
  • Market Cap: $25.92 billion
  • Outstanding Shares: 224,556,000
Average Prices:
  • 50 Day Moving Avg: $120.96
  • 200 Day Moving Avg: $124.82
  • 52 Week Range: $109.12 - $157.02
P/E:
  • Trailing P/E Ratio: 54.94
  • Foreward P/E Ratio: 17.49
  • P/E Growth: 1.20
Sales & Book Value:
  • Annual Revenue: $3.25 billion
  • Price / Sales: 7.97
  • Book Value: $39.54 per share
  • Price / Book: 2.92
Profitability:
  • EBIDTA: $1.26 billion
  • Net Margins: 12.46%
  • Return on Equity: 10.58%
  • Return on Assets: 6.69%
Debt:
  • Debt-to-Equity Ratio: 0.37%
  • Current Ratio: 2.51%
  • Quick Ratio: 2.16%
Misc:
  • Average Volume: 1.89 million shs.
  • Beta: 1.39
  • Short Ratio: 1.71
 

Frequently Asked Questions for Alexion Pharmaceuticals (NASDAQ:ALXN)

What is Alexion Pharmaceuticals' stock symbol?

Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN."

How will Alexion Pharmaceuticals' stock buyback program work?

Alexion Pharmaceuticals declared that its board has initiated a stock buyback plan on Sunday, April 9th 2017, which permits the company to repurchase $1,000,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to buy up to 3.4% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company's board of directors believes its stock is undervalued.

How were Alexion Pharmaceuticals' earnings last quarter?

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) released its earnings results on Thursday, April, 27th. The company reported $1.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.05 by $0.33. The company had revenue of $870 million for the quarter, compared to analyst estimates of $826.63 million. Alexion Pharmaceuticals had a return on equity of 10.58% and a net margin of 12.46%. Alexion Pharmaceuticals's revenue for the quarter was up 24.3% on a year-over-year basis. During the same period in the prior year, the firm posted $1.11 earnings per share. View Alexion Pharmaceuticals' Earnings History.

When will Alexion Pharmaceuticals make its next earnings announcement?

Alexion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, July, 26th 2017. View Earnings Estimates for Alexion Pharmaceuticals.

What guidance has Alexion Pharmaceuticals issued on next quarter's earnings?

Alexion Pharmaceuticals updated its FY17 earnings guidance on Thursday, April, 27th. The company provided EPS guidance of $5.10-5.30 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.25. The company issued revenue guidance of $3.4-3.5 billion, compared to the consensus revenue estimate of $3.47 billion.

Where is Alexion Pharmaceuticals' stock going? Where will Alexion Pharmaceuticals' stock price be in 2017?

24 equities research analysts have issued 1-year price objectives for Alexion Pharmaceuticals' shares. Their forecasts range from $120.00 to $221.00. On average, they expect Alexion Pharmaceuticals' stock price to reach $169.14 in the next year. View Analyst Ratings for Alexion Pharmaceuticals.

What are analysts saying about Alexion Pharmaceuticals stock?

Here are some recent quotes from research analysts about Alexion Pharmaceuticals stock:

  • 1. Barclays PLC analysts commented, "provides support to the patient association in Brazil in the form of unrestricted educational grants and in accordance with local laws and regulations and industry code." In addition, the spokesperson confirmed that Alexion has not been charged with any criminal or civil misconduct.Investors Shrug Barclays' CallShortly after reports of Alexion's raid on Monday, analysts at Barclays offered a quick take on how investors should react.Barclays' Geoff Meacham suggested that while the headline report looks "onerous," the report shouldn't be viewed as a major fundamental concern. The analyst cited "good Soliris growth" (5/9/2017)
  • 2. Cowen and Company analysts commented, "We recently hosted investor meetings with CEO Ludwig Hantson, CFO Dave." (4/28/2017)
  • 3. According to Zacks Investment Research, "Alexion's guidance for 2017 was tepid signaling the slowdown of sales. Sales of Soliris have weakened in recent quarters thereby dampening growth prospects. Soliris’ revenue growth will also be impacted by the enrollment ramp-up of trials on ALXN1210 (by $70 million - $110 million). The drug is also witnessing access challenges in Latin America. Additionally, Alexion has faced significant setbacks in its attempts to expand Soliris’ label. Moreover, ongoing focus on drug pricing and sudden departure of its key executives in the middle of an internal probe into the sales practices related to Soliris are concerning. The probe revealed a material weakness in Alexion’s internal controls over financial reporting. Shares of Alexion have underperformed the broader industry in the past one year. Estimates have reduced lately ahead of the Q1 earnings results. Alexion has a positive record of earnings surprises in recent quarters." (4/18/2017)
  • 4. Royal Bank of Canada analysts commented, "Appointment doesn't have the brand recognition investors may have hoped for; it does however end period of uncertainty and provides stability. Appointment of a CEO a net positive, signals end to period of unrest and uncertainty for ALXN: We view today's news as an incremental net positive for ALXN. On the positive side, we believe that bringing in a permanent new CEO, who during his due diligence must have kicked the tires, looked under the hood, and (presumably) checked on everything that caused one of biotech's most smoothly running engines to flutter, ends the period of unrest and uncertainty for the troubled orphan disease company. It should allow the organization to focus on execution, vs. wondering what is going on at the helm. This calming effect can probably also be felt by investors. In addition, Mr. Hantson brings a solid operational background through his years at Baxter, Novartis and J&J. On the other hand, given that the Alexion seat should be considered one of the most sought after CEO positions in biotech, we can't blame investors who may feel anywhere from disappointed to concerned that the company wasn't able to attract a more recognizable 'brand' name to fill its top role. Overall, however, we believe that, appearances aside, having someone at the seat (and Mr. Hantson certainly has very legitimate, relevant experience and we would have viewed him as a viable candidate) is better than having an interim CEO for an extended period of time. Therefore, we view today's news as an incremental net positive, since it allows the ball to start moving forward in the Alexion story and removes the leadership overhang, allowing investors to focus on the fundamentals again. With the stock trading around 10% of its 52-week low, and with most of the issues of the recent months behind it, we view current levels as attractive, and we recommend owning the shares here and reiterate our Outperform rating on ALXN." (3/27/2017)
  • 5. Instinet analysts commented, "We believe that ALXN is attractively valued following underperformance despite the company's strong fundamentals, including 18% YoY revenue growth on 22% volume growth. We see 2017 headwinds from ALXN1210 trial cannibalization of Soliris growth abating around 2H17, leading to upside in expectations ahead of new approval-driven growth in 2018. Approvals in gMG in 3Q17 and NMO data 1Q18, along with metabolic franchise traction, will, in our view, drive multiple expansion and upside to ALXN estimates over the next 12 months, supporting our Buy rating. We estimate that gMG and NMO each represents a $1.1bn market opportunity." (3/1/2017)

Who are some of Alexion Pharmaceuticals' key competitors?

Who owns Alexion Pharmaceuticals stock?

Alexion Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (0.00%), BlackRock Inc. (0.00%), Vanguard Group Inc. (0.00%), State Street Corp (5.03%), Jennison Associates LLC (4.28%) and Ameriprise Financial Inc. (2.75%). Company insiders that own Alexion Pharmaceuticals stock include Alvin S Parven, Ann M Veneman, Carsten Thiel, Clare Carmichael, David Hallal, Edward Miller, Heidi L Wagner, John B Moriarty, Julie O'neill, Leonard Bell, Martin Mackay, Saqib Islam and Vikas Sinha. View Institutional Ownership Trends for Alexion Pharmaceuticals.

Who sold Alexion Pharmaceuticals stock? Who is selling Alexion Pharmaceuticals stock?

Alexion Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Waddell & Reed Financial Inc., Alliancebernstein L.P., Parametric Portfolio Associates LLC, TCW Group Inc., Thrivent Financial For Lutherans, Sachem Head Capital Management LP and TIAA CREF Investment Management LLC. Company insiders that have sold Alexion Pharmaceuticals stock in the last year include Alvin S Parven, Carsten Thiel, Clare Carmichael, David Hallal, Edward Miller, Heidi L Wagner, John B Moriarty, Julie O'neill, Leonard Bell and Vikas Sinha. View Insider Buying and Selling for Alexion Pharmaceuticals.

Who bought Alexion Pharmaceuticals stock? Who is buying Alexion Pharmaceuticals stock?

Alexion Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Jennison Associates LLC, State Street Corp, Marshall Wace North America L.P., Ameriprise Financial Inc., Vanguard Group Inc., Bank of New York Mellon Corp and Renaissance Technologies LLC. View Insider Buying and Selling for Alexion Pharmaceuticals.

How do I buy Alexion Pharmaceuticals stock?

Shares of Alexion Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Alexion Pharmaceuticals stock cost?

One share of Alexion Pharmaceuticals stock can currently be purchased for approximately $115.42.

Analyst Ratings

Consensus Ratings for Alexion Pharmaceuticals (NASDAQ:ALXN) (?)
Ratings Breakdown: 6 Hold Ratings, 17 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.79)
Consensus Price Target: $169.14 (46.54% upside)

Analysts' Ratings History for Alexion Pharmaceuticals (NASDAQ:ALXN)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/9/2017Raymond James Financial, Inc.Reiterated RatingStrong-Buy$176.00LowView Rating Details
5/9/2017Barclays PLCReiterated RatingOverweight$155.00LowView Rating Details
5/1/2017BMO Capital MarketsReiterated RatingOutperform$158.00HighView Rating Details
4/28/2017Cowen and CompanyReiterated RatingOutperform$180.00MediumView Rating Details
3/30/2017InstinetReiterated RatingBuy$148.00LowView Rating Details
3/27/2017Royal Bank of CanadaReiterated RatingOutperform$177.00LowView Rating Details
3/20/2017Leerink SwannReiterated RatingOutperformLowView Rating Details
3/1/2017NomuraInitiated CoverageBuyN/AView Rating Details
2/16/2017Oppenheimer Holdings Inc.Reiterated RatingHoldN/AView Rating Details
2/17/2017Credit Suisse Group AGReiterated RatingBuy$160.00N/AView Rating Details
2/7/2017JPMorgan Chase & Co.Set Price TargetBuy$170.00N/AView Rating Details
1/7/2017Robert W. BairdReiterated RatingNeutral$145.00N/AView Rating Details
1/6/2017Piper Jaffray CompaniesReiterated RatingBuy$176.00N/AView Rating Details
12/25/2016Jefferies Group LLCSet Price TargetHold$120.00N/AView Rating Details
12/23/2016Deutsche Bank AGReiterated RatingBuy$164.00 -> $160.00N/AView Rating Details
12/13/2016WedbushReiterated RatingNeutral$135.00N/AView Rating Details
12/13/2016Morgan StanleyDowngradeOverweight -> Equal WeightN/AView Rating Details
11/30/2016FBR & CoReiterated RatingMarket Perform$130.00N/AView Rating Details
11/10/2016Goldman Sachs Group IncReiterated RatingBuy$158.00N/AView Rating Details
10/4/2016Brean CapitalInitiated CoverageBuy$221.00N/AView Rating Details
9/20/2016Citigroup IncBoost Price TargetBuy$154.00 -> $155.00N/AView Rating Details
7/29/2016Stifel NicolausLower Price TargetBuy$195.00 -> $182.00N/AView Rating Details
7/13/2016SunTrust Banks, Inc.Lower Price TargetBuy$220.00 -> $197.00N/AView Rating Details
6/6/2016Bank of America CorpReiterated RatingBuyN/AView Rating Details
1/7/2016BTIG ResearchDowngradeBuy -> NeutralN/AView Rating Details
6/23/2015Sanford C. BernsteinSet Price TargetBuy$267.00N/AView Rating Details
(Data available from 5/22/2015 forward)

Earnings

Earnings History for Alexion Pharmaceuticals (NASDAQ:ALXN)
Earnings by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)
Earnings History by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/26/2017        
4/27/2017Q1 2017$1.05$1.38$826.63 million$870.00 millionViewN/AView Earnings Details
2/16/2017Q416$1.25$1.26$840.69 million$831.00 millionViewN/AView Earnings Details
10/27/2016Q316$1.04$1.23$787.07 million$799.00 millionViewListenView Earnings Details
7/28/2016Q216$0.91$1.13$743.18 million$753.00 millionViewListenView Earnings Details
4/28/2016Q116$1.13$1.11$710.98 million$701.00 millionViewListenView Earnings Details
2/3/2016Q415$1.10$1.13$703.42 million$701.00 millionViewN/AView Earnings Details
10/29/2015Q315$1.01$1.16$668.33 million$666.60 millionViewListenView Earnings Details
7/30/2015Q215$1.31$1.44$628.03 million$636.00 millionViewListenView Earnings Details
4/23/2015Q115$1.18$1.28$594.40 million$600.30 millionViewN/AView Earnings Details
1/29/2015Q414$1.17$1.13$589.85 million$599.00 millionViewListenView Earnings Details
10/23/2014Q314$1.05$1.27$541.93 million$555.10 millionViewListenView Earnings Details
7/24/2014Q214$0.99$0.99$509.54 million$512.50 millionViewListenView Earnings Details
4/24/2014Q114$1.26$1.53$560.22 million$566.60 millionViewListenView Earnings Details
1/30/2014Q413$0.83$0.87$430.08 million$441.90 millionViewListenView Earnings Details
10/24/2013Q313$0.79$0.83$395.10 million$400.40 millionViewListenView Earnings Details
7/25/2013Q2 2013$0.68$0.73$364.80 million$370.10 millionViewListenView Earnings Details
4/25/2013Q1 2013$0.61$0.65$336.56 million$338.90 millionViewListenView Earnings Details
2/14/2013Q4 2012$0.52$0.60$316.49 million$320.50 millionViewListenView Earnings Details
10/24/2012$0.47$0.60ViewN/AView Earnings Details
7/25/2012$0.36$0.47ViewN/AView Earnings Details
4/24/2012$0.38$0.45ViewN/AView Earnings Details
2/9/2012$0.33$0.41ViewN/AView Earnings Details
10/20/2011$0.28$0.37ViewN/AView Earnings Details
7/21/2011$0.26$0.29ViewN/AView Earnings Details
4/21/2011$0.51$0.59ViewN/AView Earnings Details
2/10/2011$0.50$0.51ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Alexion Pharmaceuticals (NASDAQ:ALXN)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$1.04$1.04$1.04
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Alexion Pharmaceuticals (NASDAQ:ALXN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Alexion Pharmaceuticals (NASDAQ:ALXN)
Insider Ownership Percentage: 4.41%
Institutional Ownership Percentage: 94.98%
Insider Trades by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)
Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)
Insider Trades by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/1/2017Clare CarmichaelEVPSell2,179$131.66$286,887.14View SEC Filing  
3/1/2017Heidi L WagnerSVPSell994$131.65$130,860.10View SEC Filing  
3/1/2017Leonard BellDirectorSell3,978$131.96$524,936.88View SEC Filing  
2/28/2017Carsten ThielEVPSell125$74.52$9,315.00View SEC Filing  
2/28/2017Edward MillerSVPSell590$131.48$77,573.20View SEC Filing  
2/28/2017Leonard BellDirectorSell2,738$131.71$360,621.98View SEC Filing  
2/27/2017Edward MillerSVPSell260$131.20$34,112.00View SEC Filing  
2/27/2017John B MoriartyEVPSell612$131.20$80,294.40View SEC Filing  
2/9/2017John B MoriartyEVPSell167$126.84$21,182.28View SEC Filing  
2/9/2017Leonard BellDirectorSell246$126.84$31,202.64View SEC Filing  
2/7/2017Heidi L WagnerSVPSell1,932$125.97$243,374.04View SEC Filing  
2/7/2017John B MoriartyEVPSell3,538$125.79$445,045.02View SEC Filing  
2/7/2017Leonard BellDirectorSell8,725$125.97$1,099,088.25View SEC Filing  
1/10/2017Leonard BellDirectorSell100$144.99$14,499.00View SEC Filing  
1/9/2017Leonard BellDirectorSell40,065$138.48$5,548,201.20View SEC Filing  
1/5/2017Alvin S ParvenDirectorSell22,659$138.35$3,134,872.65View SEC Filing  
12/12/2016John B MoriartyEVPSell1,044$118.61$123,828.84View SEC Filing  
12/9/2016Carsten ThielEVPSell2,308$130.00$300,040.00View SEC Filing  
11/14/2016Heidi L WagnerSVPSell59$115.10$6,790.90View SEC Filing  
11/4/2016Leonard BellDirectorSell37,317$140.38$5,238,560.46View SEC Filing  
10/31/2016Leonard BellDirectorSell1,300$135.28$175,864.00View SEC Filing  
10/14/2016Carsten ThielEVPSell4,584$120.28$551,363.52View SEC Filing  
10/3/2016Carsten ThielEVPSell29$122.41$3,549.89View SEC Filing  
10/3/2016Heidi L WagnerSVPSell120$122.41$14,689.20View SEC Filing  
9/13/2016Carsten ThielEVPSell3,225$128.67$414,960.75View SEC Filing  
9/9/2016Edward MillerSVPSell367$128.32$47,093.44View SEC Filing  
9/6/2016Carsten ThielEVPSell1,000$125.94$125,940.00View SEC Filing  
9/2/2016Julie O'neillEVPSell650$126.29$82,088.50View SEC Filing  
8/30/2016Clare CarmichaelEVPSell1,000$127.76$127,760.00View SEC Filing  
8/22/2016Alvin S ParvenDirectorSell15,000$136.53$2,047,950.00View SEC Filing  
8/15/2016Alvin S ParvenDirectorSell700$135.51$94,857.00View SEC Filing  
8/8/2016Clare CarmichaelEVPSell165$137.14$22,628.10View SEC Filing  
8/8/2016David HallalCEOSell332$137.14$45,530.48View SEC Filing  
8/8/2016Heidi L WagnerSVPSell222$137.14$30,445.08View SEC Filing  
8/8/2016Leonard BellDirectorSell1,010$137.14$138,511.40View SEC Filing  
8/8/2016Vikas SinhaCFOSell277$137.14$37,987.78View SEC Filing  
6/13/2016John B MoriartyEVPSell918$135.72$124,590.96View SEC Filing  
5/16/2016Martin MackayEVPSell4,097$139.20$570,302.40View SEC Filing  
5/13/2016Heidi L WagnerSVPSell53$138.65$7,348.45View SEC Filing  
4/1/2016David HallalCEOSell1,414$135.88$192,134.32View SEC Filing  
2/29/2016Clare CarmichaelEVPSell1,312$138.91$182,249.92View SEC Filing  
2/29/2016David HallalCEOSell2,014$138.93$279,805.02View SEC Filing  
2/29/2016Edward MillerSVPSell329$138.91$45,701.39View SEC Filing  
2/29/2016Leonard BellDirectorSell3,995$138.92$554,985.40View SEC Filing  
2/29/2016Vikas SinhaCFOSell1,122$138.91$155,857.02View SEC Filing  
2/8/2016David HallalCEOSell11,297$140.50$1,587,228.50View SEC Filing  
2/8/2016Heidi L. WagnerSVPSell2,108$140.93$297,080.44View SEC Filing  
2/8/2016Julie O'neillEVPSell2,858$141.83$405,350.14View SEC Filing  
2/8/2016Leonard BellDirectorSell15,872$139.58$2,215,413.76View SEC Filing  
2/8/2016Vikas SinhaCFOSell6,547$140.04$916,841.88View SEC Filing  
2/5/2016Edward MillerSVPSell1,051$143.02$150,314.02View SEC Filing  
12/29/2015Leonard BellDirectorSell35,000$190.66$6,673,100.00View SEC Filing  
12/17/2015Leonard BellDirectorSell70,000$187.69$13,138,300.00View SEC Filing  
12/11/2015Ann M VenemanDirectorSell895$187.48$167,794.60View SEC Filing  
12/11/2015John B. MoriartyEVPSell943$182.73$172,314.39View SEC Filing  
12/8/2015Leonard BellDirectorSell70,000$188.20$13,174,000.00View SEC Filing  
12/8/2015Saqib IslamEVPSell950$190.00$180,500.00View SEC Filing  
11/25/2015Leonard BellDirectorSell35,000$181.89$6,366,150.00View SEC Filing  
10/26/2015Saqib IslamEVPSell1,558$168.44$262,429.52View SEC Filing  
9/9/2015Leonard BellDirectorSell1,050$180.10$189,105.00View SEC Filing  
6/18/2015Leonard BellDirectorSell27,835$179.63$5,000,001.05View SEC Filing  
3/19/2015Leonard BellCEOSell15,952$188.07$3,000,092.64View SEC Filing  
3/2/2015Julie O'neillEVPSell11,665$101.49$1,183,880.85View SEC Filing  
3/2/2015Leonard BellCEOSell1,230$180.34$221,818.20View SEC Filing  
2/10/2015Clare CarmichaelEVPSell1,490$171.15$255,013.50View SEC Filing  
2/10/2015David HallalCOOSell1,980$171.15$338,877.00View SEC Filing  
2/10/2015Leonard BellCEOSell5,740$171.15$982,401.00View SEC Filing  
2/10/2015Vikas SinhaCFOSell1,985$171.15$339,732.75View SEC Filing  
2/9/2015Clare CarmichaelEVPSell1,665$173.75$289,293.75View SEC Filing  
2/9/2015David HallalCOOSell2,920$173.93$507,875.60View SEC Filing  
2/9/2015Leonard BellCEOSell8,660$173.98$1,506,666.80View SEC Filing  
2/9/2015Vikas SinhaCFOSell2,703$174.18$470,808.54View SEC Filing  
2/4/2015David HallalCOOSell1,373$174.18$239,149.14View SEC Filing  
2/4/2015Leonard BellCEOSell5,223$174.29$910,316.67View SEC Filing  
2/4/2015Vikas SinhaCFOSell1,571$174.19$273,652.49View SEC Filing  
12/18/2014David HallalCOOSell5,494$182.03$1,000,072.82View SEC Filing  
12/18/2014Leonard BellCEOSell30,415$179.73$5,466,487.95View SEC Filing  
12/18/2014Vikas SinhaCFOSell5,493$182.08$1,000,165.44View SEC Filing  
12/9/2014Leonard BellCEOSell133,320$198.26$26,432,023.20View SEC Filing  
12/4/2014Clare CarmichaelSVPSell10,000$196.25$1,962,500.00View SEC Filing  
12/4/2014William R KellerDirectorSell5,000$196.25$981,250.00View SEC Filing  
12/3/2014Vikas SinhaCFOSell75,000$198.96$14,922,000.00View SEC Filing  
11/3/2014David HallalCOOSell30,000$190.01$5,700,300.00View SEC Filing  
11/3/2014Martin MackayEVPSell9,375$191.52$1,795,500.00View SEC Filing  
11/3/2014Saqib IslamSVPSell28,125$190.50$5,357,812.50View SEC Filing  
11/3/2014Vikas SinhaCFOSell49,307$192.63$9,498,007.41View SEC Filing  
10/27/2014John B MoriartySVPSell10,000$189.49$1,894,900.00View SEC Filing  
10/27/2014Stephen P SquintoEVPSell5,910$188.58$1,114,507.80View SEC Filing  
10/6/2014John B MoriartySVPSell10,000$179.00$1,790,000.00View SEC Filing  
10/3/2014Stephen P SquintoEVPSell10,025$172.41$1,728,410.25View SEC Filing  
9/26/2014Leonard BellCEOSell60,000$165.12$9,907,200.00View SEC Filing  
9/24/2014Stephen P SquintoEVPSell76$159.50$12,122.00View SEC Filing  
9/18/2014Leonard BellCEOSell44,435$160.60$7,136,261.00View SEC Filing  
9/10/2014Leonard BellCEOSell12,199$165.38$2,017,470.62View SEC Filing  
9/8/2014Leonard BellCEOSell197,801$165.32$32,700,461.32View SEC Filing  
8/27/2014Leonard BellCEOSell5,912$169.17$1,000,133.04View SEC Filing  
8/25/2014Andreas RummeltDirectorSell5,052$170.53$861,517.56View SEC Filing  
8/15/2014Leonard BellCEOSell70,000$167.99$11,759,300.00View SEC Filing  
8/13/2014Leonard BellCEOSell105,000$160.71$16,874,550.00View SEC Filing  
8/12/2014Leonard BellCEOSell80,458$160.16$12,886,153.28View SEC Filing  
8/4/2014David HallalEVPSell1,349$158.00$213,142.00View SEC Filing  
8/4/2014Leonard BellCEOSell5,145$157.88$812,292.60View SEC Filing  
8/4/2014Vikas SinhaCFOSell1,525$157.82$240,675.50View SEC Filing  
7/30/2014Leonard BellCEOSell127,289$162.93$20,739,196.77View SEC Filing  
7/29/2014Leonard BellCEOSell1,200$164.93$197,916.00View SEC Filing  
7/28/2014Leonard BellCEOSell105,600$162.38$17,147,328.00View SEC Filing  
6/20/2014Leonard BellCEOSell90,280$163.60$14,769,808.00View SEC Filing  
6/12/2014Martin MackayEVPSell25,000$166.42$4,160,500.00View SEC Filing  
6/5/2014William R KellerDirectorSell3,425$170.00$582,250.00View SEC Filing  
5/27/2014Leonard BellCEOSell70,000$166.16$11,631,200.00View SEC Filing  
5/20/2014Leonard BellCEOSell70,000$155.96$10,917,200.00View SEC Filing  
5/14/2014Martin MackayEVPSell3,574$160.85$574,877.90View SEC Filing  
5/13/2014Alvin ParvenDirectorSell12,276$160.78$1,973,735.28View SEC Filing  
4/29/2014Leonard BellCEOSell70,000$156.20$10,934,000.00View SEC Filing  
2/10/2014Stephen SquintoEVPSell7,055$158.04$1,114,972.20View SEC Filing  
2/7/2014David HallalEVPSell1,620$155.57$252,023.40View SEC Filing  
2/7/2014Frank WrightSVPSell1,098$155.57$170,815.86View SEC Filing  
2/7/2014Joseph MadriDirectorSell30,000$159.00$4,770,000.00View SEC Filing  
2/7/2014Leonard BellCEOSell4,620$155.56$718,687.20View SEC Filing  
2/4/2014Leonard BellCEOSell11,790$154.50$1,821,555.00View SEC Filing  
2/4/2014Stephen SquintoEVPSell36,989$155.12$5,737,733.68View SEC Filing  
2/4/2014Vikas SinhaCFOSell3,552$154.47$548,677.44View SEC Filing  
1/29/2014Leonard BellCEOSell2,660$133.81$355,934.60View SEC Filing  
1/29/2014Stephen SquintoEVPSell1,118$133.31$149,040.58View SEC Filing  
1/22/2014Leonard BellCEOSell156,436$140.80$22,026,188.80View SEC Filing  
1/10/2014Leonard BellCEOSell19,155$134.98$2,585,541.90View SEC Filing  
12/19/2013Leonard BellCEOSell175,000$126.38$22,116,500.00View SEC Filing  
10/28/2013Stephen P SquintoEVPSell41,037$124.06$5,091,050.22View SEC Filing  
10/28/2013Vikas SinhaCFOSell50,000$122.97$6,148,500.00View SEC Filing  
9/16/2013Joseph MadriDirectorSell30,000$115.00$3,450,000.00View SEC Filing  
9/16/2013Leonard BellCEOSell3,500$115.00$402,500.00View SEC Filing  
9/13/2013Stephen SquintoEVPSell1,000$114.37$114,370.00View SEC Filing  
9/4/2013Leonard BellCEOSell1,850$110.07$203,629.50View SEC Filing  
9/3/2013Leonard BellCEOSell33,150$110.19$3,652,798.50View SEC Filing  
8/30/2013Clare CarmichaelSVPSell1,237$107.58$133,076.46View SEC Filing  
8/16/2013Leonard BellCEOSell140,000$106.08$14,851,200.00View SEC Filing  
8/5/2013Leonard BellCEOSell2,919$116.87$341,143.53View SEC Filing  
8/2/2013Stephen P SquintoEVPSell14,125$115.33$1,629,036.25View SEC Filing  
7/30/2013Leonard BellCEOSell212,737$114.62$24,383,914.94View SEC Filing  
7/30/2013Stephen P SquintoEVPSell1,120$110.86$124,163.20View SEC Filing  
7/12/2013David HallalEVPSell50,000$120.00$6,000,000.00View SEC Filing  
7/1/2013Stephen P SquintoEVPSell44,125$94.97$4,190,551.25View SEC Filing  
5/22/2013R Douglas NorbyDirectorSell40,000$102.77$4,110,800.00View SEC Filing  
5/20/2013William R KellerDirectorSell9,770$103.00$1,006,310.00View SEC Filing  
5/14/2013Leonard BellCEOSell31,113$105.74$3,289,888.62View SEC Filing  
5/13/2013Leonard BellCEOSell41,220$100.85$4,157,037.00View SEC Filing  
4/10/2013Leonard BellCEOSell26,700$100.24$2,676,408.00View SEC Filing  
2/4/2013Leonard BellCEOSell11,880$96.27$1,143,687.60View SEC Filing  
2/4/2013Stephen P SquintoEVPSell2,572$95.68$246,088.96View SEC Filing  
2/4/2013Vikas SinhaCFOSell3,483$95.81$333,706.23View SEC Filing  
1/15/2013Leonard BellCEOSell35,000$98.58$3,450,300.00View SEC Filing  
10/31/2012Patrice CoissacSVPSell84,764$91.16$7,727,086.24View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Alexion Pharmaceuticals (NASDAQ:ALXN)
Latest Headlines for Alexion Pharmaceuticals (NASDAQ:ALXN)
Source:
DateHeadline
finance.yahoo.com logoStocks That Fell to 3-Year Lows in the Week of May 19
finance.yahoo.com - May 22 at 3:29 PM
finance.yahoo.com logoCramer's lightning round: It's OK to own this stock — as long as you're diversified
finance.yahoo.com - May 19 at 3:28 PM
finance.yahoo.com logoWhy Stay Bullish On Gilead
finance.yahoo.com - May 19 at 3:28 PM
finance.yahoo.com logo5 Reasons Big Biotech Could Gain 25%-30%
finance.yahoo.com - May 19 at 3:28 PM
finance.yahoo.com logoAmgen, Gilead, Biogen Won't Lead The Biotech Boom — So Who Will?
finance.yahoo.com - May 19 at 3:28 PM
zacks.com logoAlexion's (ALXN) Strensiq Results Positive in Long-Term Study
www.zacks.com - May 19 at 9:35 AM
finance.yahoo.com logoFor millions of Chinese with rare diseases, some relief in sight
finance.yahoo.com - May 19 at 9:35 AM
seekingalpha.com logoAlexion: Shares Look Ready To Bounce - Seeking Alpha
seekingalpha.com - May 18 at 3:29 PM
finance.yahoo.com logoGlancy Prongay & Murray LLP Commences Investigation on Behalf of Alexion Pharmaceuticals, Inc. Investors
finance.yahoo.com - May 18 at 12:12 PM
nasdaq.com logoAlexion's (ALXN) Strensiq Results Positive in Long-Term Study - Nasdaq
www.nasdaq.com - May 17 at 8:35 PM
finance.yahoo.com logoAlexion's (ALXN) Strensiq Results Positive in Long-Term Study
finance.yahoo.com - May 17 at 8:35 PM
finance.yahoo.com logoHere's Why Omeros Corporation Is Surging Again Today
finance.yahoo.com - May 17 at 12:27 PM
businesswire.com logoRady Children's Institute for Genomic Medicine and Alexion Pharmaceuticals Partner to Speed the Diagnosis of Rare ... - Business Wire (press release)
www.businesswire.com - May 16 at 8:35 PM
streetinsider.com logoAlexion Pharma (ALXN) Says Long-term Data Confirm Benefits of ... - StreetInsider.com
www.streetinsider.com - May 16 at 7:22 AM
finance.yahoo.com logoRady Children’s Institute for Genomic Medicine and Alexion Pharmaceuticals Partner to Speed the Diagnosis of Rare Genetic Disorders in Newborns
finance.yahoo.com - May 16 at 7:22 AM
streetinsider.com logoAlexion Pharma (ALXN) Says Long-term Data Confirm Benefits of Treatment with Strensiq in HPP
www.streetinsider.com - May 15 at 3:28 PM
finance.yahoo.com logoLong-term Data Confirm Benefits of Treatment with Strensiq® (asfotase alfa) in Adolescents and Adults with Hypophosphatasia (HPP) Through Five Years
finance.yahoo.com - May 15 at 3:28 PM
finance.yahoo.com logoAlexion Global Headquarters Earns Highest LEED® Green Building Certification
finance.yahoo.com - May 12 at 1:47 AM
finance.yahoo.com logoAlexion Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ALXN-US : May 11, 2017
finance.yahoo.com - May 11 at 3:44 PM
finance.yahoo.com logoALXN1210 Is Expected to Boost Alexion Pharmaceuticals’ Revenue
finance.yahoo.com - May 11 at 3:43 PM
finance.yahoo.com logoAnalysts’ Latest Recommendations for Alexion and Its Peers
finance.yahoo.com - May 10 at 3:39 PM
finance.yahoo.com logoAlexion Pharmaceuticals Projects Robust 2017 Revenue Performance
finance.yahoo.com - May 10 at 3:39 PM
finance.yahoo.com logoNew Patient Starts Expected to Drive Soliris’s Revenue in 2017
finance.yahoo.com - May 10 at 3:39 PM
seekingalpha.com logoAlexion Pharmaceuticals: Post-Earnings Analysis - Seeking Alpha
seekingalpha.com - May 10 at 9:24 AM
finance.yahoo.com logoAlexion Shares Under Pressure Amid Brazilian Office Raid; Barclays Says Buy The Dip
finance.yahoo.com - May 9 at 3:29 PM
finance.yahoo.com logoAlexion to Present at the Bank of America Merrill Lynch 2017 Health Care Conference
finance.yahoo.com - May 9 at 3:29 PM
americanbankingnews.com logoAlexion Pharmaceuticals' (ALXN) Strong-Buy Rating Reiterated at Raymond James Financial, Inc.
www.americanbankingnews.com - May 9 at 9:48 AM
americanbankingnews.com logoAlexion Pharmaceuticals, Inc. (ALXN) Given "Overweight" Rating at Barclays PLC
www.americanbankingnews.com - May 9 at 8:16 AM
nasdaq.com logoBrazilian police search Alexion offices in fraud probe
www.nasdaq.com - May 8 at 8:27 PM
nasdaq.com logoBrazilian police search Alexion offices in drug sales probe
www.nasdaq.com - May 8 at 3:27 PM
finance.yahoo.com logoAlexion Raided by Brazilian Police in Sales Practices Probe
finance.yahoo.com - May 8 at 3:27 PM
finance.yahoo.com logoBrazilian Police Raid Alexion Offices in Sales Probe
finance.yahoo.com - May 8 at 3:27 PM
finance.yahoo.com logoBioMarin: Is Profitability On The Horizon?
finance.yahoo.com - May 8 at 3:27 PM
seekingalpha.com logoAlexion Pharmaceuticals drops after raid in Brazil
seekingalpha.com - May 8 at 11:50 AM
americanbankingnews.com logoSomewhat Favorable News Coverage Extremely Likely to Affect Alexion Pharmaceuticals (ALXN) Share Price
www.americanbankingnews.com - May 3 at 10:26 AM
americanbankingnews.com logoAlexion Pharmaceuticals, Inc. (ALXN) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 2 at 10:48 PM
americanbankingnews.com logoAlexion Pharmaceuticals, Inc. (ALXN) Earns "Outperform" Rating from BMO Capital Markets
www.americanbankingnews.com - May 1 at 4:42 PM
finance.yahoo.com logoAlexion Pharmaceuticals, Inc. :ALXN-US: Earnings Analysis: Q1, 2017 By the Numbers : May 1, 2017
finance.yahoo.com - May 1 at 3:32 PM
americanbankingnews.com logoAlexion Pharmaceuticals (ALXN) Given Coverage Optimism Score of 0.27
www.americanbankingnews.com - April 30 at 1:32 PM
americanbankingnews.com logoCowen and Company Reaffirms Outperform Rating for Alexion Pharmaceuticals, Inc. (ALXN)
www.americanbankingnews.com - April 29 at 1:26 PM
finance.yahoo.com logoAlexion (ALXN) Tops Q1 Earnings, Revenues; Ups '17 View - Yahoo Finance
finance.yahoo.com - April 28 at 9:28 PM
finance.yahoo.com logoAlexion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ALXN-US : April 28, 2017
finance.yahoo.com - April 28 at 4:25 PM
finance.yahoo.com logoEdited Transcript of ALXN earnings conference call or presentation 27-Apr-17 2:00pm GMT
finance.yahoo.com - April 28 at 4:25 PM
rttnews.com logoAlexion Pharma Increases 2017 Earnings Guidance - Quick Facts
www.rttnews.com - April 28 at 1:52 AM
seekingalpha.com logoAlexion Pharmaceuticals (ALXN) Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - April 28 at 1:52 AM
finance.yahoo.com logoAlexion Reports First Quarter 2017 Results
finance.yahoo.com - April 28 at 1:52 AM
finance.yahoo.com logoAlexion Rises More Than 5% After Beating Consensus
finance.yahoo.com - April 28 at 1:52 AM
seekingalpha.com logoAlexion - Among The Best Risk/Reward In Biotech? - Seeking Alpha
seekingalpha.com - April 27 at 8:51 PM
nasdaq.com logoAlexion Pharmaceuticals Inc. Reports 39% Gain In Q1 Profit - Nasdaq
www.nasdaq.com - April 27 at 3:50 PM
nasdaq.com logoAlexion (ALXN) Tops Q1 Earnings, Revenues; Ups '17 View - Nasdaq
www.nasdaq.com - April 27 at 3:50 PM

Social

Alexion Pharmaceuticals (ALXN) Chart for Monday, May, 22, 2017

This page was last updated on 5/22/2017 by MarketBeat.com Staff